COMPANY ANNOUNCEMENT - No. 11-2022 - Inside information -
BIRKERØD,
In Q1, 2022, ViroGates’ revenue was TDKK 3,197, increasing by 54% compared to Q1, 2021, which is the highest quarterly revenue recorded in the company’s history. The increase was primarily driven by COVID-19 customers following the EMA approval of suPAR-guided anakinra treatment in
The COVID-19 pandemic continued to be a challenge in the traditional emergency department (ED) segment, but the focused efforts on converting COVID-19 customers to more general ED triaging were starting to show results. The net impact of COVID-19 remains uncertain.
Financial results in Q1, 2022
The financial results in Q1, 2022, continued to show an increasing interest in the clinically relevant suPARnostic® products (Q1, 2021 results in brackets):
- Revenue increased by 54% to TDKK 3,197 (TDKK 2,076)
- Operating expenses decreased by -6% to TDKK -5,819 (TDKK -6,224)
- Operating loss decreased by -25% to TDKK -3,435 (TDKK -4,600)
- Net loss decreased by -31% to TDKK -2,966 (TDKK -4,274)
- Cash and cash equivalents at the end of the period amounted to TDKK 10,870 (TDKK 23,562)
Business highlights in Q1, 2022
The business highlights indicate an increasing footprint in
- Welcomed several new clinical routine customers in
Germany ,Spain , andFinland – announced a total of 33 customers across nine markets -
Announced partnership with
Italy -based DIESSE for the suPARnostic® ELISA product to be implemented on theChorus Trio platform - Issued warrants to key non-management employees
This announcement is a summary and should be read in conjunction with ViroGates’ Interim Report for Q1, 2022, published on
For further information, please contact:
CEO,
Tel. (+45) 2226 1355, email: jk@virogates.com
Certified Advisor:
Västra Hamnen Corporate Finance
Per Lönn
Tel. (+46) 40 200 250, email: per.lonn@vhcorp.se
About
The company was founded in 2000. Headquartered in
About suPAR and suPARnostic®
suPAR is a biomarker detected by
The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing global demands on health systems and tightening healthcare budgets necessitate efficiency improvements and innovative hospital solutions. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by up to 34% and reducing the average hospital length of stay by up to 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on
Disclosure regulation
Prospects about the future reflect
Contacts
Jakob Knudsen , CEO, +45 2226 1355, jk@virogates.com
Attachments
- 20220504-
ViroGates -Interim Report Q1 2022_vF.pdf
© Ritzau Denmark, source